-
公开(公告)号：US09580493B2
公开(公告)日：2017-02-28
申请号：US14128497
申请日：2012-06-22
申请人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
发明人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , G01N33/68
CPC分类号： C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
摘要： Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供抗人α-突触核蛋白特异性结合分子，例如抗体或抗原结合片段，其变体或衍生物，作为与其相关的方法。 还提供了结合人α-突触核蛋白上的特异性N末端和C-末端表位的抗人α-突触核蛋白结合分子。 本文所述的结合分子可分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US08940276B2
公开(公告)日：2015-01-27
申请号：US13140699
申请日：2009-12-21
申请人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： A61K39/395 , C12P21/08 , C12N9/96 , C07K16/18
CPC分类号： C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20150232542A1
公开(公告)日：2015-08-20
申请号：US14592391
申请日：2015-01-08
申请人： Andreas WEIHOFEN , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas WEIHOFEN , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： C07K16/18 , A61K49/16 , A61K45/06 , G01N33/68 , A61K39/395
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K49/16 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92 , G01N33/6896 , G01N2333/4703 , G01N2800/2814 , G01N2800/2821 , G01N2800/2835
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20110300077A1
公开(公告)日：2011-12-08
申请号：US13140699
申请日：2009-12-21
申请人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
发明人： Andreas Weihofen , Jan Grimm , Roger Nitsch , Christoph Hock
IPC分类号： A61K39/395 , C12P21/08 , C12N9/96 , C12N5/10 , C12N1/21 , A61K49/16 , G01N33/577 , C07K16/18 , A61P25/16 , A61P25/28 , A61P25/00 , A61K49/00 , C12N15/13 , C12N1/19
CPC分类号： C07K16/18 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要： Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供的是人α-突触核蛋白特异性自身抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与α-突触核蛋白特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可以分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20140369940A1
公开(公告)日：2014-12-18
申请号：US14128497
申请日：2012-06-22
申请人： Andreas Weihofen , Jan Grimm , Cristoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
发明人： Andreas Weihofen , Jan Grimm , Cristoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
CPC分类号： C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
摘要： Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供抗人α-突触核蛋白特异性结合分子，例如抗体或抗原结合片段，其变体或衍生物，作为与其相关的方法。 还提供了结合人α-突触核蛋白上的特异性N末端和C-末端表位的抗人α-突触核蛋白结合分子。 本文所述的结合分子可分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20100202968A1
公开(公告)日：2010-08-12
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
IPC分类号： A61K49/00 , G01N33/50 , C07K16/00 , C07H21/00 , C12N15/74 , C12N5/10 , C12P21/02 , A61K31/7088 , A61K35/12 , A61K39/395 , A61K39/00 , A61P25/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
公开(公告)号：US09283271B2
公开(公告)日：2016-03-15
申请号：US13992840
申请日：2011-12-19
申请人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Marcel Maier
发明人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Marcel Maier
IPC分类号： A61K39/395 , A61K39/00 , C07K14/435 , C07K16/40 , C12N9/02 , A61K45/06 , A61K47/48 , A61K49/08 , A61K51/10 , G01N33/573
CPC分类号： C07K16/40 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K47/6871 , A61K49/085 , A61K51/10 , A61K2039/505 , C07K14/435 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12N9/0089 , G01N33/573 , G01N33/577 , G01N33/6893 , G01N2333/90283 , G01N2800/28 , G01N2800/285
摘要： Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供新型人铜 - 锌超氧化物歧化酶，也称为超氧化物歧化酶1或SOD1，特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与SOD1特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于SOD1靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US20140301945A1
公开(公告)日：2014-10-09
申请号：US13992840
申请日：2011-12-19
申请人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Tobias Welt , Jordan McAfoose , Marcel Maier
发明人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Tobias Welt , Jordan McAfoose , Marcel Maier
IPC分类号： A61K39/395 , A61K49/08 , G01N33/573 , A61K45/06 , A61K47/48 , C12N9/02 , A61K51/10 , C07K16/40
CPC分类号： C07K16/40 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K47/6871 , A61K49/085 , A61K51/10 , A61K2039/505 , C07K14/435 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12N9/0089 , G01N33/573 , G01N33/577 , G01N33/6893 , G01N2333/90283 , G01N2800/28 , G01N2800/285
摘要： Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
摘要翻译： 提供新型人铜 - 锌超氧化物歧化酶，也称为超氧化物歧化酶1或SOD1，特异性抗体以及其片段，衍生物和变体以及与之相关的方法。 还公开了与SOD1特异性抗体相关的测定，试剂盒和固体支持物。 抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于SOD1靶向免疫治疗和诊断的药物和诊断组合物中。
-
公开(公告)号：US08906367B2
公开(公告)日：2014-12-09
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
10.发明申请ANKYRIN G AND MODULATORS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS 审中-公开ANKYRIN G及其治疗神经损伤性疾病的调节剂公开(公告)号：US20140044644A1
公开(公告)日：2014-02-13
申请号：US14000454
申请日：2012-02-21
IPC分类号： A61K39/395 , G01N33/68 , A61K31/7088 , A61K49/00 , A61K38/17 , A61K31/713
CPC分类号： A61K39/3955 , A01K2267/0312 , A61K31/7088 , A61K31/713 , A61K38/17 , A61K38/1709 , A61K39/0007 , A61K49/0004 , A61K2039/55566 , C07K16/18 , C12N2770/36143 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/2821
摘要： The present invention generally relates to the technical field of medicine, in particular to the field of neurodegenerative, neurological and protein misfolding disorders such as amyloidosis. By establishing a role of ankG in APP processing the method of the present invention provides a new insight into the role of ankG in AD pathology and provides ankG as a target, drug, diagnostic agent and particularly as a vaccine in the treatment and diagnosis of the pathogenesis of Alzheimer's disease (AD).
摘要翻译： 本发明一般涉及医学技术领域，特别涉及神经变性，神经和蛋白质错误折叠疾病如淀粉样变性的领域。 通过在APP处理中建立ankG的作用，本发明的方法提供了对adkG在AD病理学中的作用的新见解，并提供ankG作为靶标，药物，诊断剂，特别是作为疫苗治疗和诊断 阿尔茨海默氏病（AD）的发病机制。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.032 秒)
